Archive:
Der Diabetes mellitus gilt mit einer Prävalenz von ca. 5 bis 6 % der Bevölkerung als eine Volkskrankheit. Er ist unter anderem eine häufige Ursache für Neuerblindung, hämodialysepflichtige Niereninsuffizienz sowie Amputationen an den unteren Extremitäten. Darüber hinaus ist er mit einem circa zwei- bis dreifach erhöhten Risiko für Herzinfarkt und Schlaganfall assoziiert. Die Diagnose subsumiert […]
01.08.2010
Cover interview with Dr. Rolf-Ulrich Schlenker, deputy. Chairman of the Board of BARMER GEK
01.06.2010
Discount contracts influence the supply of medicines to those insured by other health insurance companies
01.06.2010
Seit 2002 ist Jens Spahn Mitglied des Deutschen Bundestages und seit November 2005 Vorsitzender Arbeitsgruppe Gesundheit der CDU/CSU-Bundestagsfraktion, Obmann der CDU/CSU-Fraktion im Ausschuss für Gesundheit und gesundheitspolitischer Sprecher der CDU/CSU-Bundestagsfraktion im Deutschen Bundestag. Der Jungpolitiker, von Hause aus Bankkaufmann, der neben seiner Tätigkeit in Berlin 2008 den Bachelor of Arts (B.A.) in Politikwissenschaft erworben hat, […]
01.06.2010
Drug contracts are the instrument of selective contracting in the area of outpatient drug care. They offer opportunities to reduce costs, open up new markets and improve the quality of care. The overall potential of discount contracts has not yet been leveraged. All those involved are asked to get involved, to develop new forms of contract or to adapt existing contracts to meet needs.
01.06.2010
Discount contracts have played a prominent role in the pharmaceutical supply of statutory health insurance (GKV). This competitive field has undergone dramatic change in many respects. Not only contract design, implementation, but also legal assessment and public perception have changed. Implementation problems from the beginning have largely been resolved. The savings from the contracts are essential for the GKV - every statutory health insurance company has reported numerous contracts. The article provides an overview of the experiences of the German BKK.
01.06.2010
The instrument of drug discount contracts was implemented in the statutory health insurance (GKV) system in order to curb drug spending in the outpatient sector. The GKV Competition Strengthening Act (GKV-WSG), which came into force on April 1, 2007, paved the way for health insurance companies to be able to conclude discount agreements with pharmaceutical manufacturers more effectively than before. Since then, pharmacists have had to give preference to discounted medications. Ideally, both manufacturers and health insurance companies can benefit from such discount agreements.